{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:01:32Z","timestamp":1793394092074,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.bcmd.2023.102724","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T03:05:15Z","timestamp":1673579115000},"page":"102724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Daratumumab as a novel treatment option in refractory ITP"],"prefix":"10.1016","volume":"99","author":[{"given":"Ilze","family":"Vernava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens A.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bcmd.2023.102724_bb0005","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1749-6632.1965.tb18984.x","article-title":"Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies","volume":"124","author":"Shulman","year":"1965","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"21","key":"10.1016\/j.bcmd.2023.102724_bb0010","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","article-title":"Clinical updates in adult immune thrombocytopenia","volume":"129","author":"Lambert","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcmd.2023.102724_bb0015","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2023.102724_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103820","article-title":"Recent advances in the mechanisms and treatment of immune thrombocytopenia","volume":"76","author":"Provan","year":"2022","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.bcmd.2023.102724_bb0025","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm921","article-title":"T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura","volume":"9","author":"Olsson","year":"2003","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.bcmd.2023.102724_bb0030","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00277-016-2703-1","article-title":"Bone marrow niche in immune thrombocytopenia: a focus on megakaryopoiesis","volume":"95","author":"Khodadi","year":"2016","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.bcmd.2023.102724_bb0035","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.V83.4.1024.1024","article-title":"Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura","volume":"83","author":"He","year":"1994","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcmd.2023.102724_bb0040","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2141.1986.tb05552.x","article-title":"Complement activation in vitro by antiplatelet antibodies in chronic immune thrombocytopenic purpura","volume":"63","author":"Tsubakio","year":"1986","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.bcmd.2023.102724_bb0045","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.bcmd.2023.102724_bb0050","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bcmd.2023.102724_bb0055","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/08916930802397848","article-title":"BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura","volume":"42","author":"Zhou","year":"2009","journal-title":"Autoimmunity"},{"issue":"9","key":"10.1016\/j.bcmd.2023.102724_bb0060","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ajh.20951","article-title":"The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab","volume":"82","author":"Kuwana","year":"2007","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.bcmd.2023.102724_bb0065","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3389\/fimmu.2019.02458","article-title":"Challenges and opportunities for consistent classification of human B cell and plasma cell populations","volume":"18","author":"Sanz","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcmd.2023.102724_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28010","article-title":"Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia","volume":"67","author":"Even-Or","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.bcmd.2023.102724_bb0075","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.16171","article-title":"Post-allogeneic transplant Evans syndrome successfully treated with daratumumab","volume":"187","author":"Blennerhassett","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bcmd.2023.102724_bb0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40348-021-00114-y","article-title":"Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature","volume":"8","author":"Driouk","year":"2021","journal-title":"Mol. Cell Pediatr."},{"issue":"5","key":"10.1016\/j.bcmd.2023.102724_bb0085","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/bjh.17565","article-title":"Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series","volume":"194","author":"Khandelwal","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.bcmd.2023.102724_bb0090","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.3324\/haematol.2021.279232","article-title":"Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia","volume":"106","author":"Crickx","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bcmd.2023.102724_bb0095","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/bloodadvances.2019001215","article-title":"Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review","volume":"4","author":"Migdady","year":"2020","journal-title":"Blood Adv."},{"issue":"19","key":"10.1016\/j.bcmd.2023.102724_bb0100","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2018020883","article-title":"Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation","volume":"2","author":"Schuetz","year":"2018","journal-title":"Blood Adv."},{"issue":"19","key":"10.1016\/j.bcmd.2023.102724_bb0105","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMoa1807438","article-title":"Daratumumab for delayed red-cell engraftment after allogeneic transplantation","volume":"379","author":"Chapuy","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bcmd.2023.102724_bb0110","doi-asserted-by":"crossref","first-page":"E216","DOI":"10.1002\/ajh.25515","article-title":"Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab","volume":"94","author":"Bathini","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.bcmd.2023.102724_bb0115","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/s41409-019-0664-4","article-title":"Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation","volume":"55","author":"Rautenberg","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.bcmd.2023.102724_bb0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/ejh.13343","article-title":"Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab","volume":"104","author":"Salas","year":"2020","journal-title":"Eur. J. Haematol."},{"issue":"12","key":"10.1016\/j.bcmd.2023.102724_bb0125","article-title":"The immunomodulatory effect and clinical efficacy of daratumumab in a patient with cold agglutinin disease","volume":"1","author":"Zaninoni","year":"2021","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.bcmd.2023.102724_bb0130","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bcmd.2023.102724_bb0135","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3390\/jcm10051004","article-title":"Emerging therapies in immune thrombocytopenia","volume":"10","author":"Audia","year":"2021","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.bcmd.2023.102724_bb0140","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153580","article-title":"High-affinity autoreactive plasma cells disseminate through multiple organs in patients with immune thrombocytopenic purpura","volume":"132","author":"Canales-Herrerias","year":"2022","journal-title":"J. Clin. Invest."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979623000013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979623000013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:36:22Z","timestamp":1761050182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979623000013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":28,"alternative-id":["S1079979623000013"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2023.102724","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daratumumab as a novel treatment option in refractory ITP","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2023.102724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102724"}}